Immunic Inc (NASDAQ:IMUX) announced that it will present clinical trial data from its lead asset vidofludimus calcium (IMU-838) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.
"Having two poster presentations on our lead asset, vidofludimus calcium, at the prestigious ACTRIMS Forum is a testament to the strength of the data we have generated," Immunic CEO Dr. Daniel Vitt said in a statement.
The CALLIPER trial assessed the safety and efficacy of vidofludimus calcium in patients with progressive multiple sclerosis.
Dr. Vitt highlighted that in the company’s interim analysis of this trial, it observed a clear separation of vidofludimus calcium from placebo in serum neurofilament light chain (NfL) levels across all PMS patients as well as all subtypes.
“We believe that the data set provides biomarker evidence that vidofludimus calcium's activity extends beyond the previously observed anti-inflammatory effects, further reinforcing its neuroprotective potential,” he said.
“The next inflection point for this potentially first-in-class Nurr1 activator for the treatment of PMS is the CALLIPER top-line data, expected in April of next year."
Meanwhile, vidofludimus calcium was being evaluated as a potential treatment for COVID-19 in the CALVID-1 trial. COVID-positive trial participants received placebo or 45mg vidofludimus calcium for 14 days in addition to start-of-care treatment.
“Our second poster on the phase 2 CALVID-1 trial illustrates that, because of vidofludimus calcium's potential ability to prevent the reactivation of the Epstein-Barr virus (EBV), it may also contribute to the reduction of fatigue in MS patients,” Dr. Vitt commented.
“We aim to confirm the ability of vidofludimus calcium to influence fatigue and EBV reactivation in our ongoing phase 3 ENSURE trials in relapsing MS patients and hope that this may create yet another differentiating feature for this medication candidate."
ACTRIMS is taking place from February 29 to March 2 in West Palm Beach, Florida.